Summary:
- Bristol-Myers Squibb's revenue outpaces forecasts but earnings per share miss estimates.
- The stock is projected to have an upside of over 16% based on current market analysis.
- Despite industry growth, the company's annual revenue is expected to decline over the next three years.
Bristol-Myers Squibb (BMY, Financial) recently announced a revenue performance exceeding expectations by 4.6%. However, the company faced a setback as earnings per share (EPS) fell short by 3.8%. Looking ahead, Bristol-Myers Squibb foresees a 4.9% annual decrease in revenue over the next three years. This projection is in stark contrast to the anticipated 8.8% growth within the broader U.S. pharmaceutical industry. Consequently, shares have seen a 2.7% decline.
Wall Street Analysts Forecast
In evaluating Bristol-Myers Squibb Co.'s (BMY, Financial) potential, data from 21 analysts suggest an average target price of $55.88. This target represents an optimistic upside of 16.67% from the current trading price of $47.90. The highest estimate stands at $68.00, while the lowest is $33.10. For more comprehensive estimate data, visit the Bristol-Myers Squibb Co. (BMY) Forecast page.
On the recommendation scale, Bristol-Myers Squibb Co. (BMY, Financial) garners an average brokerage recommendation of 2.7, placing it within the "Hold" category. This rating is part of a scale ranging from 1 to 5, where 1 is a Strong Buy and 5 is a Sell.
Delving into GuruFocus estimates, the projected GF Value for Bristol-Myers Squibb Co. (BMY, Financial) in one year is $56.43. This projection implies a potential upside of 17.81% from the current stock price of $47.90. The GF Value is derived from the historical trading multiples of the stock, its past business growth, and future performance estimates. For more in-depth information, visit the Bristol-Myers Squibb Co. (BMY) Summary page.
